Both indications for the CTLA-4 inhibitor were approved by the FDA in 2022.
Samantha Brongiel, PharmD, BCOP
Advertisement
Articles by Samantha Brongiel, PharmD, BCOP
The agent is representative of a new class of drug, ImmTAC.
Advertisement
Latest Updated Articles
Addition of Tremelimumab-actl to Durvalumab-Based Regimen May Broaden Clinical Activity in uHCC, mNSCLCPublished: February 15th 2023 | Updated:
Tebentafusp-tebn Use in HLA-A*02:01–Positive Unresectable or Metastatic Uveal MelanomaPublished: October 18th 2022 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
2
Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer
3
Under Pressure: A Brief Overview of the Updated Hypertension Guidelines
4
Cholesterol-HDL-Glucose Index Linked to Type 2 Diabetes Prevalence in Adults
5
